Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

NCT05281263 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: CPI-RSV-F Vaccine (BLB-201)

Sponsor

Blue Lake Biotechnology Inc.